XOMA Reports 2013 Operational Highlights and Fourth Quarter and Full-Year 2013 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
XOMA (XOMA) Target Cut to $9 at Jefferies
March 5, 2014 8:37 AM ESTJefferies analyst Biren Amin cut is price target on XOMA, Ltd. (NASDAQ: XOMA) from $11 to $9 after the company announced that the gevokizumab program for erosive osteoarthritis of the hand (EOA) is being discontinued after gevokizumab failed to demonstrate benefit in the two PII trials. The... More
XOMA (XOMA) Sinks Over 15% on Trade Resumption
March 4, 2014 5:29 PM ESTXOMA (NASDAQ: XOMA) has resumed trading and is down 15.2% after reporting that it will not purse gevokizumab development for the broad EOA indication. In addition, XOMA reported a large fourth quarter loss.... More
XOMA Ltd (XOMA) Posts Q4 GAAP Loss of 55c/Share
March 4, 2014 5:00 PM ESTXOMA Ltd (NASDAQ: XOMA) reported Q4 EPS of ($0.55), which may not compare with the analyst estimate of ($0.19). Revenue for the quarter came in at $8.45 million versus the consensus estimate of $7.92 million.
Of the $0.55 per share loss, $35.3 million, or $0.37 per share, was related directly to the... More
